[Histomorphologic and respiratory aspects of acute lung injury in rats induced by experimental sepsis and under pentoxifylline treatment].
OBJECTIVE
Respiratory repercussion on acute lung injury in a model of induced sepsis intraperitoneally.


METHODS
Fifteen animals taken at random were submitted to adult male Wistar rats. The rats were randomly divided into 3 groups (n=15): Group C - control group received only mechanical ventilation; Group S - rats received live Escherichia coli (E. coli) intraperitoneally (septic) and after 6 hours they were treated with normal saline infusion and ventilated with a low tidal volume. Group S+PTX - rats received live Escherichia coli intraperitoneally (septic) and after 6 hours they were treated with pentoxifylline (PTX) infusion and ventilated with a low tidal volume. All animals were ventilated during 180 minutes. We analyzed the arterial blood gases, gravimetric indices and histomorphometric analysis.


RESULTS
Blood gases, wet to dry ratios, and total protein concentrations in the bronchoalveolar lavage were analyzed in all experimental groups. In the end of the experiment the partial pressure of oxygen was higher in the GS+PTX (460,0 +/- 38,2 mmHg) compared with GS (336,0 +/- 14,6 mmHg). Pentoxifylline with low tidal volume attenuated significantly total protein in the bronchoalveolar lavage. The septal diameter was significantly reduced in the group GS compared with group GS+PTX (P < 0,05).


CONCLUSIONS
The pentoxifylline ameliorated the oxygenation and decreased the deleterious effects of sepsis in the associated mechanical ventilation.
Oliveira
Wagner Rogerio Souza de
WR
Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP.
Cavassani
Sâmia Santos
SS
Maganhin
Carla Cristina
CC
Carbonel
Adriana Aparecida Ferraz
AA
Simões
Manuel Jesus
MJ
Simões
Ricardo Santos
RS
Junqueira
Virginia Berlanga Campos
VB
Oliveira-Júnior
Itamar Souza de
IS
D055371:Acute Lung Injury / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid; D004927:Escherichia coli Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D010100:Oxygen / Q000378:metabolism*; D010431:Pentoxifylline / Q000627:therapeutic use*; D011650:Pulmonary Alveoli / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D012121:Respiration, Artificial; D018805:Sepsis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D010100:Oxygen; D010431:Pentoxifylline